NCT03574012

Brief Summary

This pilot trial studies how well education and mobile health applications work in reducing the effects of cancer treatment on the heart in participants with blood cancers that are in remission. Education and mobile health applications may be effective ways to manage heart health and to reduce future heart disease risk in participants with blood cancers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2018

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 29, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

August 31, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 22, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 16, 2020

Completed
Last Updated

January 23, 2024

Status Verified

September 1, 2020

Enrollment Period

1.4 years

First QC Date

June 19, 2018

Last Update Submit

January 22, 2024

Conditions

Outcome Measures

Primary Outcomes (5)

  • Enrollment rate among participants approached

    Up to 1 year

  • Retention rate among participants enrolled

    Retention is defined as completion of patient questionnaire and in-person assessment after 4-month intervention

    Up to 1 year

  • Participation in Facebook group

    Number of participants who log onto the group page and participate at least one time (e.g., view a post, post something themselves, respond to a post \[e.g., "like" a post\], etc.)

    Up to 1 year

  • Participation in Fitbit physical activity tracking

    Number of participants who submit step count data on at least 50% of eligible days

    Up to 1 year

  • Participation in Healthwatch diet tracking

    Number of participants who provide dietary data on at least 75% of eligible days

    Up to 1 year

Study Arms (2)

Control Group (general health information, fitness tracker)

ACTIVE COMPARATOR

Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.

Device: Monitoring DeviceOther: Informational InterventionOther: Questionnaire Administration

Intervention Group (individualized information, tracker)

EXPERIMENTAL

Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.

Device: Monitoring DeviceOther: Informational InterventionOther: Questionnaire Administration

Interventions

Use Fitbit tracker

Control Group (general health information, fitness tracker)Intervention Group (individualized information, tracker)

Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform

Intervention Group (individualized information, tracker)

Ancillary studies

Control Group (general health information, fitness tracker)Intervention Group (individualized information, tracker)

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Prior diagnosis of an acute leukemia or lymphoma or any receipt of HCT for a malignant condition.
  • At time of approach, \>= 5 years from initial cancer diagnosis or \>= 5 years from first HCT, whichever is later.
  • Currently in remission and not on any active anti-cancer therapies (survivors receiving maintenance tyrosine kinase inhibitors are NOT eligible).
  • Able to read, write, and speak English.
  • Access to smart phone or computer with internet access.
  • Presence of at least 1 CV risk factor:
  • Currently on medication for hypertension, or
  • Currently on medication for cholesterol or triglyceride, or
  • Currently on medication for diabetes, or
  • Currently not physically active (self-reported average \< 30 minutes/day), or
  • Currently smoking.
  • Ability to understand and the willingness to provide informed consent.

You may not qualify if:

  • Pre-existing ischemic heart disease (includes angina if documented in electronic medical record \[EMR\]) or ongoing symptomatic cardiomyopathy (those with asymptomatic cardiomyopathy may be allowed to participate if they do not have any current activity restrictions, but we will seek physician clearance for any submaximal exercise testing).
  • Active systemic treatment for graft versus host disease.
  • Currently pregnant. However, participants enrolled who become pregnant after randomization can remain on the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location

Related Publications (1)

  • Chow EJ, Doody DR, Di C, Armenian SH, Baker KS, Bricker JB, Gopal AK, Hagen AM, Ketterl TG, Lee SJ, Reding KW, Schenk JM, Syrjala KL, Taylor SA, Wang G, Neuhouser ML, Mendoza JA. Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial. J Cancer Surviv. 2021 Aug;15(4):554-563. doi: 10.1007/s11764-020-00949-w. Epub 2020 Oct 10.

MeSH Terms

Conditions

Lymphoma

Interventions

Monitoring, Physiologic

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Eric Chow

    Fred Hutch/University of Washington Cancer Consortium

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2018

First Posted

June 29, 2018

Study Start

August 31, 2018

Primary Completion

January 22, 2020

Study Completion

June 16, 2020

Last Updated

January 23, 2024

Record last verified: 2020-09

Locations